Effectiveness and acceptability of a 24-h interval versus a 48-h interval between mifepristone intake and misoprostol administration for in-hospital abortion at 9–20 gestational weeks: an international, open-label, randomised, controlled, non-inferio
Effectiveness and acceptability of a 24-h interval versus a 48-h interval between mifepristone intake and misoprostol administration for in-hospital abortion at 9–20 gestational weeks: an international, open-label, randomised, controlled, non-inferio
Kristina Gemzell‐Danielsson, Margit Endler, H.M. Vemer, Unnop Jaisamrarn et al.
Citations
5 citations
Journal
The Lancet Global Health
Topics
Reproductive Health and Contraception
Field-Weighted Citation Impact (FWCI)
2.71
article
Effectiveness and acceptability of a 24-h interval versus a 48-h interval between mifepristone intake and misoprostol administration for in-hospital abortion at 9–20 gestational weeks: an international, open-label, randomised, controlled, non-inferio
Kristina Gemzell‐Danielsson, Margit Endler, H.M. Vemer, Unnop Jaisamrarn, A. Metin Gülmezog̈lu, Toan Anh Ngo, Suneeta Mittal, Phutrakool Phanupong, Du Van Du
article en
5 citations
Abstract
No abstract available for this paper.
Publication Tag
The Lancet Global HealthVol. 13(1)
Institutions
Chulalongkorn University (TH), Fortis Memorial Research Institute (IN), Concept Foundation (CH), Vietnam National Children's Hospital (VN)
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
Effectiveness and acceptability of a 24-h interval versus a 48-h interval between mifepristone intake and misoprostol administration for in-hospital abortion at 9–20 gestational weeks: an international, open-label, randomised, controlled, non-inferio — Kristina Gemzell‐Danielsson, Margit Endler, et al. · The Lancet Global Health (2024) | TGRS Research Map | TGRS